Verrica Pharmaceuticals VRCA 深 沪
已收盘 08-22 16:00:00 美东时间
5.465
-0.275
-4.79%
华盛通- 最 高5.78
- 今 开5.78
- 成交量 5.07万股
- 最 低 5.40
- 昨 收 5.74
- 总市值 5.05亿
- 52周最高 24.40
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 3.816
- 委 比 -60.00%
- 总股本 9249.10万
- 历史最高 232.90
- 量 比 1.65
- 振 幅 6.62%
- 历史最低 3.816
- 每 手 1
- 风险率 2.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Verrica Pharmaceuticals Q2 Adj. EPS $0.25 Beats $(0.07) Estimate, Sales $12.702M Beat $4.367M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.07) by 457.14 percent. This is a 180.65 percent increase over losses of $(0.31) per
08-13 04:02
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
What to Expect from Verrica Pharmaceuticals's Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) is preparing to release its quarterly ear...
08-12 04:03
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Verrica Pharmaceuticals Inc. will host a conference call on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update. Participants can join via phone using the conference ID: VERRICA or access the live webcast on www.verrica.com. A replay will be available for 90 days. Verrica develops dermatology treatments, including YCANTH® for molluscum contagiosum and common warts, and VP-315 for non-melanoma s...
08-06 11:00
Verrica Reports Record 13,434 YCANTH Applicator Units Dispensed In Q2 2025, Marking 32.8% Sequential Growth
– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q2 2025 –– Company reports receipt of $8 million milestone payment from its Japanese
07-09 19:05
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
Verrica Pharmaceuticals Inc. reported a 32.8% sequential quarterly growth in Q2 2025, with 13,434 YCANTH® dispensed applicator units sold. The company also received an $8 million milestone payment from its Japanese partner, Torii Pharmaceutical, for initiating a global Phase 3 program for common warts. YCANTH, approved by the FDA for treating molluscum contagiosum, shows strong demand driven by a focused commercial strategy, improved patient acce...
07-09 11:00
Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts
Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of
07-01 19:06
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals and Torii Pharmaceutical have amended their collaboration agreement to initiate a global Phase 3 trial for YCANTH® to treat common warts. Verrica will receive an $8 million milestone payment in July 2025 and up to $18 million in 2025 if YCANTH is approved in Japan. Torii will fund $40 million of the trial costs. The U.S. launch of the trial is expected in Q4 2025, targeting the 22 million Americans affected by common warts...
07-01 11:00
Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed
An update from Verrica Pharmaceuticals ( ($VRCA) ) is now available. On June 10...
06-13 04:50
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 pm ET in New York City. Participants can access the live webcast via the company website or provided link, with a replay available for 90 days. Verrica specializes in dermatology treatments, including YCANTH® for molluscum contagiosum and common warts, and VP-315 for non-melanoma skin cancers.
05-28 12:00
